IKT
Price:
$2.965
Market Cap:
$199.23M
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in ...[Read more]
Industry
Biotechnology
IPO Date
2020-12-23
Stock Exchange
NASDAQ
Ticker
IKT
According to Inhibikase Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.95. This represents a change of 74.54% compared to the average of -0.54 of the last 4 quarters.
The mean historical PE Ratio of Inhibikase Therapeutics, Inc. over the last ten years is -54.84. The current -0.95 PE Ratio has changed 73.24% with respect to the historical average. Over the past ten years (40 quarters), IKT's PE Ratio was at its highest in in the December 2017 quarter at 572.33. The PE Ratio was at its lowest in in the March 2018 quarter at -154.40.
Average
-54.84
Median
-20.94
Minimum
-234.31
Maximum
-0.36
Discovering the peaks and valleys of Inhibikase Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 90.85%
Maximum Annual PE Ratio = -0.36
Minimum Annual Increase = -92.50%
Minimum Annual PE Ratio = -234.31
Year | PE Ratio | Change |
---|---|---|
2023 | -0.36 | -49.44% |
2022 | -0.70 | -61.06% |
2021 | -1.81 | -92.50% |
2020 | -24.10 | 35.59% |
2019 | -17.78 | -51.77% |
2018 | -36.86 | -84.27% |
2017 | -234.31 | 90.85% |
The current PE Ratio of Inhibikase Therapeutics, Inc. (IKT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-0.96
5-year avg
-8.95
10-year avg
-54.84
Inhibikase Therapeutics, Inc.’s PE Ratio is greater than DiaMedica Therapeutics Inc. (-10.41), greater than Milestone Pharmaceuticals Inc. (-2.87), greater than Seres Therapeutics, Inc. (-5.78), greater than Oncolytics Biotech Inc. (-3.82), greater than scPharmaceuticals Inc. (-1.97), greater than aTyr Pharma, Inc. (-2.33), less than Sio Gene Therapies Inc. (0), less than Kaleido Biosciences, Inc. (-0.49), less than Tempest Therapeutics, Inc. (0), less than AN2 Therapeutics, Inc. (-0.62), less than Miromatrix Medical Inc. (-0.67), greater than PMV Pharmaceuticals, Inc. (-7.13), greater than Anebulo Pharmaceuticals, Inc. (-1.47), greater than Nutriband Inc. (-5.06), greater than Quoin Pharmaceuticals, Ltd. (-6.30), less than Longeveron Inc. (-0.28), greater than RenovoRx, Inc. (-1.33), greater than Virax Biolabs Group Limited (-3.54), less than null (-0.57),
Company | PE Ratio | Market cap |
---|---|---|
-10.41 | $225.99M | |
-2.87 | $98.92M | |
-5.78 | $164.76M | |
-3.82 | $74.38M | |
-1.97 | $169.39M | |
-2.33 | $131.12M | |
0 | $0 | |
-0.49 | $4.26K | |
0 | $37.52M | |
-0.62 | $40.49M | |
-0.67 | $92.95M | |
-7.13 | $75.81M | |
-1.47 | $40.07M | |
-5.06 | $43.12M | |
-6.30 | $2.51M | |
-0.28 | $25.99M | |
-1.33 | $31.20M | |
-3.54 | $7.42M | |
-0.57 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibikase Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Inhibikase Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Inhibikase Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Inhibikase Therapeutics, Inc. (IKT)?
What is the highest PE Ratio for Inhibikase Therapeutics, Inc. (IKT)?
What is the 3-year average PE Ratio for Inhibikase Therapeutics, Inc. (IKT)?
What is the 5-year average PE Ratio for Inhibikase Therapeutics, Inc. (IKT)?
How does the current PE Ratio for Inhibikase Therapeutics, Inc. (IKT) compare to its historical average?